Beta Bionics BBNX Non Us — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Beta Bionics in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Beta Bionics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-323777
Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the Company’s CODM. The CODM reviews financial information presented on a total company basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. As such, the Company has determined that it operates as one operating segment. The measure of segment assets is presented as total assets in the balance sheets. The Company has concluded that gross profit and net income (loss) are the primary measures of segment profit or loss used by the CODM. The CODM assesses performance for the Company, monitors budget versus actual results, and determines how to allocate resources based on net income (loss) as reported in the statements of operations and comprehensive loss. There are no other expense categories regularly provided to the CODM that are not already included in the primary financial statements herein. During the six months ended June 30, 2026 and 2025, the Company did not generate any international revenues and as of June 30, 2026 and December 31, 2025, the Company did not have a material amount of assets located outside of the United States.
Item 1. Financial Statements.
FAQ
- What is Beta Bionics's non us — revenue?
- Beta Bionics (BBNX) reported non us — revenue of $0 in Q2 2026.
- What does non us — revenue mean?
- This metric represents the total revenue generated from sales of medical devices and related services within geographic regions outside of the company's primary domestic market. It serves as a key indicator of the company's international commercial expansion and the global adoption rate of its adaptive closed-loop insulin delivery technology. Tracking this figure helps investors assess the company's ability to navigate regulatory environments and compete in diverse international healthcare markets.
Ask your AI about Beta Bionics's non us — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
